What is Innoblative Designs?
Innoblative Designs is a private medical device company dedicated to advancing surgical interventions for conditions such as breast cancer and other soft tissue diseases. The company has achieved a significant milestone with the FDA's Breakthrough Device Designation for its SIRA® RFA Electrosurgical Device. This device is engineered for precise intraoperative coagulation and ablation of soft tissue, aiming to enhance surgical outcomes by enabling localized margin control and potentially reducing the incidence of reoperations in breast-conserving procedures. Innoblative Designs is strategically expanding its platform to address further unmet clinical needs within the surgical field.
How much funding has Innoblative Designs raised?
Innoblative Designs has raised a total of $4.4M across 3 funding rounds:
Debt
$1.2M
Private Equity
$1M
Private Equity
$2.3M
Debt (2014): $1.2M, investors not publicly disclosed
Private Equity (2016): $1M, investors not publicly disclosed
Private Equity (2017): $2.3M, investors not publicly disclosed
What's next for Innoblative Designs?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Innoblative Designs. This capital infusion is expected to accelerate the commercialization of its SIRA® RFA Electrosurgical Device and support the ongoing development of its pipeline of platform devices. The company's focus on improving surgical precision and patient outcomes positions it for significant market penetration and further innovation in the competitive medical technology landscape.
See full Innoblative Designs company page
